<DOC>
	<DOCNO>NCT00960440</DOCNO>
	<brief_summary>This study test CP-690,550 safe effective rheumatoid arthritis patient take methotrexate inadequate response tumor necrosis factor inhibitor treatment .</brief_summary>
	<brief_title>Study CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor ( TNF ) Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Adults moderate severe rheumatoid arthritis stable dose methotrexate inadequate response Tumor Necrosis Factor ( TNF ) inhibitor . Pregnancy , severe acute chronic medical condition , include serious infection clinically significant laboratory abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>randomize double-blind placebo-controlled investigational drug oral therapy safety efficacy</keyword>
</DOC>